2025.05.09
“Targeting” the Advantage: A Novel Immune Checkpoint, ITPRIPL1 (CD3L1), Independent of PD-1
In the T cell–mediated antitumor immune response, the T cell receptor (TCR)–CD3 complex occupies a pivotal position; however, research on its endogenous inhibitory ligands has long remained virtually unexplored.
2025.04.22
XI News | Xichang Bio invites you to the Second Global Nuclear Medicine Development Summit!
To further advance the nuclear medicine industry and strengthen industry dialogue and collaboration, the Second Global Nuclear Medicine Development Summit, hosted by Chujie Bio, is scheduled to take place on April 23–24, 2025, at the Crowne Plaza Shanghai Saint-Norbert Hotel, located at No. 1699 Jinshajiang Road.
2025.03.31
To gain a deeper understanding of enterprises’ development needs, provide targeted support for their innovation and growth, and promote the high-quality development of the biopharmaceutical industry in Qingpu District, on March 31, 2025, Li Yujie, Deputy Director of the Qingpu District Economic Commission, led a delegation—including representatives from the Qingpu Industrial Park, Qingfa Group, Songyuan Fund, and Zhangjiang Cloud Cube—to visit Shanghai Xichang Biotechnology Co., Ltd. (hereinafter referred to as “Xichang Bio”). The team conducted an on-site inspection of the company’s R&D achievements and operational status, and held a roundtable discussion on topics such as policy support, industrial collaboration, and capital matchmaking.
2025.02.26
From February 20 to 21, the 6th ADC Drug Development Conference 2025 was successfully held amid widespread anticipation. Through meticulous preparation by the organizers, the event drew active participation from numerous industry leaders, corporate representatives, and researchers. The conference brought together cutting-edge insights and innovative technologies, and the two-day program unfolded in a vibrant atmosphere, establishing a high‑quality platform for exchange and collaboration in the field of ADC drug development.
2025.01.17
Xi News | A Steady Stream, Steadfast Progress—Annual Conference Special Edition
As the years turn and new chapters unfold, Shanghai Xichang Bio’s Spring Annual Gala was held in grand style, amid widespread anticipation and the hopeful sentiment of “May the stream flow endlessly, and steady progress lead us far.” This event was not only a heartfelt reflection on the past year but also a warm occasion for all Xichang team members to gather together and look forward to the future.
2025.01.03
As biomedical innovation continues to flourish, a wide array of academic conferences and exchange events have become platforms for intellectual dialogue, technological showcase, and collaborative expansion within the industry.
2024.10.22
Xi News | A Team-Building Journey by the Shanyan Lake — Special Feature on Corporate Team Building
In this fast-paced work environment, we’re always seeking moments that allow our hearts to rest and bring our teams closer together. On October 18, Shanghai Xichang Bio, under the rallying cry “United in Purpose, Integrated for Mutual Success,” led a group of passionate, dream‑driven colleagues on a team‑building retreat to Dianshan Lake, weaving together an unforgettable chapter of shared memories.
2025.03.27
“Targeting” the Lead: The Next PD‑1? Exploring the SOX17 Target
The immune system serves as the body’s primary defense against tumors; however, cancer cells often employ “immune evasion” mechanisms to disguise themselves and evade recognition and attack by immune cells. Although immune checkpoint therapies, exemplified by PD‑1/PD‑L1 inhibitors, have achieved remarkable progress in advanced cancers, their efficacy remains limited for early-stage tumors, such as colorectal cancer.
31
2025
/
03
26
2025
/
02
03
2025
/
01
Subscription Information
Subscribe to receive updates from Xichang News.
Shanghai Constream biotechnology Co., Ltd
Phone:021-59255902
Address: Building 2, Floors 2–3, Lane 10688, Beiqing Road, Qingpu District, Shanghai
WeChat Official Account
Copyright © 2026 Shanghai Constream biotechnology Co., Ltd.